BRIEF-Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

-16.63% Pre

-0.84%

-1.56%

-2.15%

Polyrizon Ltd. Ordinary Shares PLRZ	0.00	0.00%
Dow Jones Industrial Average DJI	0.00	0.00%
S&P 500 index SPX	0.00	0.00%
NASDAQ IXIC	0.00	0.00%

Polyrizon Ltd PLRZ.O:

POLYRIZON RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID REQUIREMENTS

Source text: ID:nGNX1PjwXC

Further company coverage: PLRZ.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Stock Ratings | Potential Upside of 284.62%! Leerink Partners initiated coverage of Ovid Therapeutics (OVID) with an "Outperform" rating and a $5 price target.

Mizuho Maintains Outperform on Immatics, Raises Price Target to $23

Gilead Sciences (GILD): Assessing Valuation After Strong Shareholder Returns and Product Pipeline Developments

BriaCell Therapeutics' Unit Partners With Research.AI To Design Anti-Cancer Isoform-selective Kinase Inhibitors

Krystal Biotech (KRYS): Assessing Valuation Following Strong Q3 Results and Global Expansion Moves

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Deloitte Fast 500 Ranking Could Be a Game Changer for Catalyst Pharmaceuticals (CPRX)

BridgeBio Pharma Independent Director Wen-Chaun Lo Sells 62% Of Holding